Reach Us +44-7426-607635

Abstract

Cladribine in the Treatment of Langerhans Cell Histiocytosis: A Summary of the Literature

Langerhans cell Histiocytosis (LCH) is a rare disease for which treatment with 2- chlorodeoxyadenosine (cladribine) has changed disease outcome. Cladribine has meanwhile been administered over two decades and is available for intravenous and subcutaneous administration. Cladribine has been administered in treatment of therapy naïve, relapsed and refractory LCH and induces high response rates, regardless of prior treatment. Literature describing the use of cladribine either alone or in combination with cytarabine is summarized herein.


Author(s):

Marlies E.H.M. van Hoef



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Flyer image
Abstracted/Indexed in
  • Index Copernicus
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Secret Search Engine Labs